ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
67.104,23
0,24%
Brent Oil
83,76
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Aeglea BioTherapeutics Inc (AGLE)

  7. Aeglea BioTherapeutics Inc (AGLE) Notícias

AGLE

Aeglea BioTherapeutics (AGLE)

Aeglea BioTherapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGLE
DataHoraFonteTítuloCódigoCompanhia
30/04/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202417:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202417:40Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
25/04/202417:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGLEAeglea BioTherapeutics Inc
02/04/202417:36Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:AGLEAeglea BioTherapeutics Inc
01/04/202417:06Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
20/03/202408:14Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGLEAeglea BioTherapeutics Inc
18/03/202417:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AGLEAeglea BioTherapeutics Inc
14/03/202417:12Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:AGLEAeglea BioTherapeutics Inc
27/11/202318:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGLEAeglea BioTherapeutics Inc
27/11/202310:30PR Newswire (US)Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNASDAQ:AGLEAeglea BioTherapeutics Inc
22/11/202319:00PR Newswire (US)Aeglea BioTherapeutics Announces Grants of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
15/11/202319:18Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:AGLEAeglea BioTherapeutics Inc
14/11/202317:13Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AGLEAeglea BioTherapeutics Inc
09/11/202318:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGLEAeglea BioTherapeutics Inc
09/11/202318:05PR Newswire (US)Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGLEAeglea BioTherapeutics Inc
30/10/202321:00PR Newswire (US)Aeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:AGLEAeglea BioTherapeutics Inc
06/10/202322:40Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:AGLEAeglea BioTherapeutics Inc
14/09/202318:03PR Newswire (US)Aeglea BioTherapeutics to Participate in Upcoming September ConferenceNASDAQ:AGLEAeglea BioTherapeutics Inc
07/09/202309:40PR Newswire (US)Aeglea BioTherapeutics Announces Reverse Stock SplitNASDAQ:AGLEAeglea BioTherapeutics Inc
05/09/202308:00PR Newswire (US)Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-JonesNASDAQ:AGLEAeglea BioTherapeutics Inc
11/08/202308:00PR Newswire (US)Aeglea BioTherapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:AGLEAeglea BioTherapeutics Inc
07/08/202317:25Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AGLEAeglea BioTherapeutics Inc
27/07/202308:00PR Newswire (US)Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica PharmaNASDAQ:AGLEAeglea BioTherapeutics Inc
06/07/202317:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AGLEAeglea BioTherapeutics Inc
30/06/202318:24Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AGLEAeglea BioTherapeutics Inc
23/06/202317:30PR Newswire (US)Aeglea BioTherapeutics Announces Grant of Inducement AwardsNASDAQ:AGLEAeglea BioTherapeutics Inc
23/06/202310:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AGLEAeglea BioTherapeutics Inc
22/06/202309:17PR Newswire (US)Aeglea BioTherapeutics Announces Acquisition of Spyre TherapeuticsNASDAQ:AGLEAeglea BioTherapeutics Inc
11/05/202308:06Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AGLEAeglea BioTherapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGLE

Seu Histórico Recente

COIN
DINTBTC
NASDAQ
FZBZQX
Cboe Vest Large Cap Deep...
TSX
4267
Lightworks
USOTC
SPNRF
Sparton Resources (PK)
ASX
CLZOA
Classic Minerals
LSE
1028
LSE
71EJ
Net.r.i. Nts52
AMEX
EVNT
Altshares Event driven ETF
COIN
GDOGGUST
Gold Dog
NYSE
IQSM
IndexIQ ETF Trus
USOTC
HAWLM
Hawaiian Electric (PK)
MRTX
NUAUSDT
Neulaut
CRTO
QUICKUSDT
Quickswap [OLD]
LSE
34JE
Sg Issuer 26
COIN
ACDCEUR
BITMOT
908139
Gl Green Tf 2,75% Dc31 A...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados